Effect of the combination of naltrexone and acamprosate on alcohol intake in mice

Psychiatry and Clinical Neurosciences

Volumn 58, Issue 1, 2004, Pages 30-36

  Kim, Sung Gon ^a   Han, Byeung Deuk ^a   Park, Je Min ^a   Kim, Myung Jung ^a   Stromberg, Michael F ^b,c  

^a Pusan National University School of Medicine   (South Korea)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acamprosate; Alcohol intake; C57BL 6 mice; Naltrexone

Indexed keywords

ACAMPROSATE; NALTREXONE;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN;

ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; MALE; MICE; MICE, INBRED C57BL; NALTREXONE; NARCOTIC ANTAGONISTS; TAURINE;

EID: 1042265349     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2004.01189.x     Document Type: Article

References (35)

1. Fuller RK, Branchey L, Brightwell DR et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986; 256: 1449-1455.
2. Hughes JC, Cook CC. The efficacy of disulfiram: a review of outcome studies. Addiction 1997; 92: 381-395.
3. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 1992; 49: 876-880.
4. O'Malley S, Jaffe A, Chang G, Schottenfeld R, Meyer R, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. Arch. Gen. Psychiatry 1992; 49: 881-887.
5. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence. Role of subject compliance. Arch. Gen. Psychiatry 1997; 54: 737-742.
6. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N. Engl. J. Med. 2001; 345: 1734-1739.
7. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Psychiatry 1996; 53: 673-680.
8. Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction 1995; 90: 1179-1188.
9. Whitworth AB, Fischer F, Lesch OM et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438-1442.
10. Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17: 1100-1109.
11. Ruilope LM, Coca A. The Role of Combination Therapy in the Treatment of Hypertension. Blood Press. Suppl. 1998; 1: 22-26.
12. Rezvani AH, Overstreet DH, Mason GA et al. Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. Alcohol Alcohol. 2000; 35: 76-83.
13. Williams LD, Mason BJ. Combination pharmacotherapy in nalmefene nonresponders. Alcohol. Clin. Exp. Res. 1997; 21: 33A.
14. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology 1997; 129: 99-111.
15. Benjamin D, Grant E, Pohrecky L. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. 1993; 621: 137-140.
16. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in nucleus accumbens. J. Neurosci. 1998; 18: 10663-10671.
17. Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog. Neurobiol. 2000; 60: 343-362.
18. Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur. J. Pharmacol. 2002; 437: 55-61.
19. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol. Clin. Exp. Res. 2001; 25: 1335-1341.
20. Heyser CJ, Schulteis G, Durbin P, Koob GF. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 1998; 18: 125-133.
21. Stromberg MF, Mackler SA, Volpicelli JR, O'Brien CP. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. Alcohol 2001; 23: 109-116.
22. Czachowski CL, Legg BH, Samson HH. Effects of acamprosate on ethanol-seeking and self-administration in the rat. Alcohol. Clin. Exp. Res. 2001; 25: 344-350.
23. Holter SM, Landgraf R, Zieglgansberger W, Spanagel R. Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation. Alcohol. Clin. Exp. Res. 1997; 21: 862-868.
24. Gewiss M, Heidbreder C, Opsomer L, Durbin P, De Witte P. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol. 1991; 26: 129-137.
25. Spanagel R, Zielgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol. Sci. 1997; 18: 54-59.
26. Walaas I. Biochemical evidence for overlapping neocortical and allocortical glutamate projections to the nucleus accumbens and rostral caudatoputamen in the rat brain. Neuroscience 1981; 6: 399-405.
27. Selim M, Bradberry CW. Effect of ethanol on extracellular 5-HT and glutamate in the nucleus accumbens and prefrontal cortex: comparison between the Lewis and Fischer 344 rat strains. Brain Res. 1996; 716: 157-164.
28. Sesack SR, Pickel VM. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J. Comp. Neurol. 1992; 320: 145-160.
29. Hu G, Duffy P, Swanson C, Ghasemzadeh MB, Kalivas PW. The regulation of dopamine transmission by metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 1999; 289: 412-416.
30. Legault M, Wise RA. Injections of N-methyl-D-aspartate into the ventral hippocampus increase extracellular dopamine in the ventral tegmental area and nucleus accumbens. Synapse 1999; 31: 241-249.
31. Krishnan-Sarin S, Portoghese P, Li T-K, Froehlich J. The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol. Biochem. Behav 1995; 52: 153-159.
32. Stromberg M, Casale M, Volpicelli L, Volpicelli J, O'Brien C. A comparison of the effects of the opioid antagonists naltrexone, naltrindole and β-funaltrexamine on ethanol consumption in the rat. Alcohol 1998; 15: 281-289.
33. Koob GF. Neural mechanisms of drug reinforcement. In: Kalivas PW, Samson HH (eds). The Neurobiology of Drug and Alcohol Addiction. New York Academy of Sciences, New York, 1992; 171-191.
34. Acquas E, Meloni M, DiChiara G. Blockage of δ-opioid receptors in the nucleus accumbens prevents ethanol-induced stimulation of dopamine release. Eur. J. Pharmacol. 1993; 230: 239-241.
35. Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl Acad. Sci. 1992; 89: 2046-2050.